Where Do We Go From Here? NeoGenomics, Inc. (NEO), TherapeuticsMD, Inc. (TXMD)

Johnson Kevin C, Director, bought 26,000 shares of the NeoGenomics, Inc. (NASDAQ:NEO) in an exchange that happened on December 21st. The stock was bought at an average price of $11.60 per share, amounting to a transaction worth $301,600. The sale was made public in a document filed with the SEC. Additionally, Former 10% Owner GENERAL ELECTRIC CO sold 10,835,145 shares of this stock in a transaction that took place on December 14th. The stock was sold at an average price of $12.00 per share, for a total exchange amounting to $130,021,740. After the transaction, the Former 10% Owner GENERAL ELECTRIC CO currently holds 0 shares of the company’s stock.

With this stock price’s latest movement, it is now -19.75% away from its 1-year high and 115.82% higher than its 1-year low price. In the past seven days, the stock price volatility for NeoGenomics, Inc. was 4.36%, whereas its volatility in the past 30 days has been 4.67%. This public company’s stock also has a beta score of 0.53. When the beta value is less/more than 1, it can imply that the stock is less/more volatile than the wider stock market – a metric that traders will surely be keeping tabs on.

NeoGenomics, Inc. (NASDAQ:NEO) most recently published its quarterly earnings results. The firm posted $0.05 earnings per share (EPS) for the three-month period, surpassing analysts’ consensus estimate of $0.02 by $0.03. The publicly-traded organization reported revenue of $69.10 million for the quarter, compared to the average analyst forecast calling for $66.32 million, which was surpassing the analyst consensus estimate.

Shares of NeoGenomics, Inc. (NEO) surged 2.07%, amounting to a gain of $0.31 per share, to finish the regular trading session at $15.28 on Thursday 01/10/2019. After beginning the session at $14.92, shares of NeoGenomics, Inc. reached as high as $15.69 during the day, while hitting a 1-day low of $14.91. Trade volume reached 3,983,075 shares against this stock’s average daily volume of 1.07M shares, with a total float of 85.91M. As a consequence of the price increase, NeoGenomics, Inc. now has a current market value of 1.43B.

TherapeuticsMD, Inc. (NASDAQ:TXMD) added 12.56% to its trading price by the close of the most recent session, jumping from its previous closing price of $4.46 to $5.02. This stock increased in value by 30.05% during the last 7-day period, and experienced a gain of 15.14% over the past 30-day period. In the past three months, this stock’s price lost by -16.33% , and subtracted -25.07% to its price during the last six months of trading. TXMD demonstrated a yearly price loss of -21.44% , while its year-to-date (YTD) price performance has been up 31.76% . This stock’s price changed by +43.22% compared to its 90-day low, and moved down -16.33% comparing to its 90-day high price.

Have a quick look on short, medium and long-term indicators. According to the Composite Indicator, Trendspotter rated the TXMD stock as “Buy”. In the short-term, TherapeuticsMD, Inc. (TXMD) has a 20-day average volume of 3,932,120 shares and short-term indicators sets the TXMD stock as “ 60% Buy ” on average basis. In the medium-term, TXMD stock has a 50-Day average volume of 3,544,038 shares and medium-term indicators gave the average rating of “ 25% Buy ”, while in the long-term period the FB stock has a 100-Day average volume of 3,030,493 shares. On average, long-term indicators rated the stock as “67% Sell ”. The overall picture from all short, medium and long-term indicators sets the TXMD stock as “24% Buy ” on average basis.

Recently, multiple brokerages have sent out reports on TXMD. JP Morgan, for example, Initiated its rating on shares of TherapeuticsMD, Inc. to a “Overweight”, while setting a $11 price target on shares of the company’s stock, according to a research note from Friday June 15th, 2018. Morgan Stanley Initiated their target price for this stock to $6, while giving the stock a “Equal-Weight” rating, as stated in a research report from Friday, September 8th, 2017. Oppenheimer, on the other hand, Upgrade a from “Perform ” to “ Outperform” rating on this stock in a research note dated Tuesday, July 11th, 2017.

In other news related to TherapeuticsMD, Inc. stock, 74.25% shares of TXMD held by institutions. The total number of institutions who held the TXMD shares was 206, according to most recent SEC filling. During the past quarter, total 176,633,116 shares held by institutions with the net change of 19,939,319 shares. In the meantime, 28 new institutions bought the shares of TherapeuticsMD, Inc. for the first time and 14 institutions sold all their holdings in the company’s common stock. 99 institutions increased their investment in the TXMD stock and 54 institutions decreased their investment in the TherapeuticsMD, Inc. (TXMD)’s stock during the last quarter.